Human Normal Immunoglobulin and Anti-D Immunoglobulin

Published date: 22 January 2021

This notice was replaced on 22 January 2021

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Opportunity (published 22 January 2021, last edited 17 February 2021)

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.

Contract summary

Industry

Immunoglobulins - 33651520

Location of contract

England, Scotland, Northern Ireland, Channel Islands, Isle of Man

Value of contract

£450,000,000

Procurement reference

CF-0101800D0O000000rwimUAA1

Published date

22 January 2021

Closing date

26 February 2021

Closing time

12am

Contract start date

1 July 2021

Contract end date

31 December 2022

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Description

NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

More information

Links

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTo/1iop.VP9FqKjRsyNnZM67iSpvSdF_AdTTmut4g7yTMg
Document No. 01 - Invitation to offer covering letter (vA3902789)

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTu/CsaY6nsr8jSS8T_W09XZMhIMXmGB7XlcxK.iDuCR35c
Document No. 04c - Management Information Template

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTt/Rrf74KgA9ViDlWHh7m4d6lyS9cBpFaD4FOx76wPI3rE
Document No. 02 - Terms of offer

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTy/xV5x.3OPIGDlAC_C36hazGJ7AkC89D_L.iL_B7IfqOw
Document No. 03 - Framework Agreement and Terms and Conditions (vA3911298)

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTp/e9VSqcfYPwgO.JxyZsrHVRxyaPSc0OXJ4InHsEQrf1M
Document No. 04a - Contract Specifics

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFUD/GKWBKTOe95OPjKXHt5DiotZ6gqRyFtfIxEDSb6PAbCw
Document No. 05b - Scoring Methodology

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTv/xcoTCU_kitfF7VIlO0HI7ndxn5oxQWWvHI140YU4HK4
Document No. 06 - Form of offer

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFU3/_PfxMkkVljvt64Fhtyrt0dkFgA2mBsrD1lNrpa5lKdA
Document No. 04b - Management Information Schedule

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTz/jp3FFxcZeuH1ETOpN1NwjbJlPr9aQ04VtY2OTebV7ic
Document No. 07a - Quality control technical sheet

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFU8/_fdzvody4SVigsUdYM8orxmWpVEqvMZ6Fq9oEc99nmU
Document No. 04d - Participating Authorities

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFTq/1fNA05JMVXCCJJ.uBq2h.HMtijW4S6vH8cGGjPpFgbw
Document No. 05a - Offer Schedule

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFUI/8N.4EjKv2l2r_NkskCZp_ZDLvsZcH8fdH6KqAVPpFyk
Document No. 07b - Guidance for performing a risk assessment of licensed medicines for the NHS

https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kFUN/mjTdmb1.XfkA1Yz0l2.i6bUD4q1i6dxgechI0LkJDhM
Document No. 08 - Confidential information schedule (vA3873357)

About the buyer

Contact name

Philip Grieve

Address

2nd Floor, Rutland House
Runcorn
WA7 2ES
GB

Email

philip.grieve@nhs.net